|
Age (years)
| | | |
|
10-49
|
146 (6.5%)
|
159 (7.1%)
|
0.07561
|
|
50-59
|
272 (12.1%)
|
256 (11.4%)
|
0.03827
|
|
60-69
|
602 (26.7%)
|
635 (28.2%)
|
0.07124
|
|
70-79
|
830 (36.8%)
|
793 (35.2%)
|
0.00596
|
|
+80
|
404 (17.9%)
|
411 (18.2%)
|
0.18397
|
|
Sex
| | | |
|
Female
|
1,490 (66.1%)
|
1,439 (63.8%)
|
0.11293
|
|
Primary hip diagnosis
| | | |
|
Primary arthrosis
|
1,647 (73.1%)
|
1,633 (72.5%)
|
0.23293
|
|
Trauma
|
323 (14.3%)
|
319 (14.2%)
|
0.28662
|
|
Other
|
284 (12.6%)
|
302 (13.4%)
|
0.00682
|
|
Comorbidity history (yes)
| | | |
|
Myocardial infarction
|
104 (4.6%)
|
113 (5.0%)
|
0.02865
|
|
Congestive heart failure
|
116 (5.2%)
|
125 (5.6%)
|
0.08273
|
|
Peripheral vascular disease
|
97 (4.3%)
|
95 (4.2%)
|
0.02495
|
|
Cerebrovascular disease
|
172 (7.6%)
|
172 (7.6%)
|
0.11255
|
|
Dementia
|
15 (0.7%)
|
8 (0.4%)
|
0.10249
|
|
Chronic pulmonary disease
|
192 (8.5%)
|
176 (7.8%)
|
0.06104
|
|
Connective tissue disease
|
169 (7.5%)
|
161 (7.1%)
|
0.02309
|
|
Peptic ulcer disease
|
129 (5.7%)
|
129 (5.7%)
|
0.07967
|
|
Mild liver disease
|
37 (1.6%)
|
30 (1.3%)
|
0.04168
|
|
Diabetes (type I and II)
|
134 (5.9%)
|
115 (5.1%)
|
0.05238
|
|
Hemiplegia
|
4 (0.2%)
|
6 (0.3%)
|
0.03791
|
|
Moderate to severe renal disease
|
55 (2.4%)
|
60 (2.7%)
|
0.06410
|
|
Diabetes with end organ damage
|
61 (2.7%)
|
47 (2.1%)
|
0.06301
|
|
Any tumor
|
260 (11.5%)
|
235 (10.4%)
|
0.09151
|
|
Leukemia
|
10 (0.4%)
|
6 (0.3%)
|
0.04010
|
|
Lymphoma
|
18 (0.8%)
|
14 (0.6%)
|
0.04218
|
|
Moderate to severe liver disease
|
11 (0.5%)
|
12 (0.5%)
|
0.03710
|
|
Metastatic solid tumor
|
39 (1.7%)
|
26 (1.2%)
|
0.08036
|
|
Fixation technique
| | | |
|
Cemented
|
1,186 (52.6%)
|
1,175 (52.1%)
|
0.03568
|
|
Cementless
|
523 (23.2%)
|
522 (23.2%)
|
0.05074
|
|
Hybrid
|
545 (24.2%)
|
557 (24.7%)
|
0.01191
|
|
Type of anesthesia
| | | |
|
Regional
|
1,753 (77.8%)
|
1,757 (78.0%)
|
0.18378
|
|
Duration of surgery (minutes)
| | | |
|
0-60
|
418 (18.5%)
|
426 (18.9%)
|
0.09806
|
|
61-120
|
1,685 (74.8%)
|
1671 (74.1%)
|
0.03567
|
|
>121
|
151 (6.7%)
|
157 (7.0%)
|
0.20997
|
|
20 hospitals performing the THR procedures*
| | |
|
Prophylaxis for heterotopic bone formation **
| | |
|
Yes
|
195 (8.7%)
|
208 (9.2%)
|
0.06109
|
|
No
|
2059 (91.4%)
|
2046 (90.7%)
|
0.06268
|
|
Preoperative Hemoglobin concentration within three months prior to surgery
| | |
|
<138.5 g/L
|
1410 (62.6%)
|
1362 (60.4%)
|
0.25041
|
|
>138.5 g/L
|
844 (37.4%)
|
892 (39.6%)
|
0.25041
|
|
Year of surgery
| | | |
|
1999
|
61 (2.7%)
|
58 (2.6%
|
0.03572
|
|
2000
|
60 (2.7%)
|
56 (2.5%)
|
0.06520
|
|
2001
|
94 (4.2%)
|
93 (4.1%)
|
0.02234
|
|
2002
|
309 (13.7%)
|
333 (14.8%)
|
0.02030
|
|
2003
|
239 (10.6%)
|
254 (11.3%
|
0.00876
|
|
2004
|
377 (16.7%)
|
392 (17.4%)
|
0.04756
|
|
2005
|
347 (15.4%)
|
333 (14.8%)
|
0.01024
|
|
2006
|
435 (19.3%)
|
411 (18.2%)
|
0.01185
|
|
2007
|
332 (14.7%)
|
324 (14.4%)
|
0.00976
|
